Life sciences · Journal article

Stage-Specific Mucin Reprogramming Across the Gastric Cancer Cascade: Unveiling Molecular Mechanisms and Novel Therapeutic Vulnerabilities

Biomolecules · September 9, 2026

Hypothesis-Generating Why this matters to you Expert discussion

Raises a question worth testing. It does not answer one.

AI Summary

This is a narrative review article that synthesizes existing literature on mucin expression changes during gastric cancer progression and their potential role in tumorigenesis, immunosuppression, and therapeutic response. The abstract describes a conceptual framework and identifies research gaps rather than reporting novel empirical findings, clinical trial results, or validated diagnostic or therapeutic strategies.

What was studied

Narrative review article. Patients with gastric cancer and precancerous gastric lesions, by analogy; no specific cohort described..

Key findings

Mucin expression, glycosylation patterns, and spatial distribution undergo systematic alterations during progression from normal gastric mucosa through precancerous lesions to gastric cancer and metastasis. Mucin reprogramming is proposed as an active biological driver of malignant transformation, immunosuppressive microenvironment shaping, and therapeutic response modulation, rather than a passive accompanying phenomenon. The review discusses potential clinical applications in early diagnosis, molecular classification, prognostic assessment, and targeted therapy of gastric cancer.

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

Clinicians should recognize this as a conceptual synthesis rather than evidence-based guidance. No specific diagnostic test, prognostic marker, or therapeutic intervention is validated or recommended in the abstract.

Plain-language summary

This is a narrative review synthesizing mechanistic observations about mucin reprogramming in gastric cancer progression; it raises questions about biological mechanisms and therapeutic potential rather than reporting primary empirical results or clinical outcomes.

Study design

As stated by the source record.

MethodsNarrative review article

Clinical bottom line

Caveats

Abstract does not report primary data, clinical outcomes, sample sizes, effect sizes, or statistical significance.
No specific diagnostic or therapeutic recommendations are quantified or validated.
Generalizability and applicability to routine clinical practice are not established.
The role of artificial intelligence in mucin phenotyping is mentioned but not detailed or evaluated in the abstract.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Literature review; no primary experimental or clinical data presented in abstract.

Directness

limited

Focuses on mechanistic mucin reprogramming; does not report direct clinical outcomes or therapeutic efficacy.

Consistency

insufficient

Abstract does not compare or reconcile findings across studies or report consensus.

Risk of bias

insufficient

Review format; no description of systematic methodology, search strategy, or bias assessment.

Sample adequacy

insufficient

No primary data collection or patient sample described in abstract.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Mucins are a class of highly glycosylated macromolecules that constitute a cornerstone of the gastrointestinal mucosal barrier and play multiple essential roles in maintaining tissue homeostasis. During the progression from normal gastric mucosa through precancerous lesions to gastric cancer and metastasis, the expression profiles, glycosylation patterns, and spatial distribution of mucins undergo systematic and programmatic alterations, a process referred to as “mucin reprogramming.” Recent studies have revealed that this reprogramming is by no means a passive bystander phenomenon accompanying tumorigenesis; rather, it is a central biological event that actively drives malignant transformation, shapes an immunosuppressive microenvironment, and influences therapeutic response. This article aims to systematically delineate the dynamic landscape of mucin expression changes during gastric cancer progression, to provide an in-depth analysis of the underlying molecular mechanisms, and to focus on its clinical value and translational potential in the early diagnosis, molecular classification, prognostic assessment, and targeted therapy of gastric cancer. In addition, this review also discusses recent applications of artificial intelligence in the precise identification of mucin phenotypic features. By integrating the latest research advances, this review seeks to provide new perspectives and a theoretical basis for a deeper understanding of the mechanisms of mucin reprogramming during gastric cancer progression and for the development of novel diagnostic and therapeutic strategies.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Kexin LuZeyu YouXiaoyang WuXiao DongHuan CaiHuakang Tu